Royalty Pharma plc
RPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $11 | $13 | $17 | $17 |
| - Cash | $1 | $0 | $2 | $2 |
| + Debt | $8 | $6 | $7 | $7 |
| Enterprise Value | $18 | $18 | $23 | $22 |
| Revenue | $2 | $2 | $2 | $2 |
| % Growth | -3.9% | 5.2% | -2.3% | – |
| Gross Profit | $2 | $2 | $2 | $2 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | $2 | $2 | $0 | $1 |
| % Margin | 68.8% | 80.2% | 18.9% | 62.5% |
| Net Income | $1 | $1 | $0 | $1 |
| % Margin | 37.9% | 48.2% | 1.9% | 27.1% |
| EPS Diluted | 1.91 | 2.53 | 0.1 | 1.49 |
| % Growth | -24.5% | 2,430% | -93.3% | – |
| Operating Cash Flow | $3 | $3 | $2 | $2 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $3 | $3 | $2 | $2 |